Lead Alzheimer's Drug Fails Phase 2 Trial; Company Halts Development and Explores Strategic Options
ABOS is trading near its 52-week low of $1.5 (6.7% below the low).
Summary
Acumen's only clinical-stage asset, sabirnetug, missed the Phase 2 ALTITUDE-AD primary endpoint — change in iADRS at 18 months versus placebo — at both the 35 mg/kg and 50 mg/kg doses. Key secondary endpoints including CDR-SB also failed, with no meaningful difference between either treatment arm and placebo. The company will stop developing sabirnetug, including the open-label extension, and is moving to cash conservation while it evaluates strategic options, including the EBD program. This is a thesis-ending event: the stock trades near its 52-week low at a small market cap, and the Q3 10-Q already carried a going-concern warning with $78.6 million in cash lasting into early 2027. The $500 million shelf filed October 26 gives capacity to raise, but with the lead program dead the value now hinges on whatever strategic alternatives emerge. Additional biomarker and imaging data are expected in the coming weeks, though management said it does not expect them to change the efficacy conclusions.
At the time of this announcement, ABOS was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $165.6M. The 52-week trading range was $1.50 to $3.60. This news item was assessed with negative market sentiment and an importance score of 10 out of 10. Source: GlobeNewswire.